Table 2. Complete blood count and inflammatory biomarkers data after initiation of lenvatinib.

	Total (n=16)
WBC count (/μL), mean ± SD	8,868±4,561
Neutrophil (%), mean ± SD	67.8±13.0
Lymphocyte (%), mean ± SD	19.4±10.8
Monocyte (%), mean ± SD	6.1±2.6
Platelet (×104/μL), mean ± SD	18.7±14.3
NLR
Mean ± SD	6.9±10.2
Median (range)	4.5 (1.2–43.4)
PLR
Mean ± SD	152.6±114.7
Median (range)	118.1 (43.0–430.3)
LMR
Mean ± SD	3.5±1.7
Median (range)	3.6 (1.0–7.0)

LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SD, standard deviation; WBC, white blood cell.